



Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes

Abu Saleh Md Moin¹ · Alexandra E. Butler¹

Published online: 10 August 2019
© The Author(s) 2019

Abstract

Purpose of Review To discuss the current understanding of “ β cell identity” and factors underlying altered identity of pancreatic β cells in diabetes, especially in humans.

Recent Findings Altered identity of β cells due to dedifferentiation and/or transdifferentiation has been proposed as a mechanism of loss of β cells in diabetes. In dedifferentiation, β cells do not undergo apoptosis; rather, they lose their identity and function. Dedifferentiation is well characterized by the decrease in expression of key β cell markers such as genes encoding major transcription factors, e.g., MafA, NeuroD1, Nkx6.1, and Foxo1, and an increase in atypical or “disallowed” genes for β cells such as lactate dehydrogenase, monocarboxylate transporter MCT1, or progenitor cell genes (Neurog3, Pax4, or Sox9). Moreover, altered identity of mature β cells in diabetes also involves transdifferentiation of β cells into other islet hormone producing cells. For example, overexpression of α cell specific transcription factor Arx or ablation of Pdx1 resulted in an increase of α cell numbers and a decrease in β cell numbers in rodents. The frequency of α - β double-positive cells was also prominent in human subjects with T2D. These altered identities of β cells likely serve as a compensatory response to enhance function/expand cell numbers and may also camouflage/protect cells from ongoing stress. However, it is equally likely that this may be a reflection of new cell formation as a frank regenerative response to ongoing tissue injury. Physiologically, all these responses are complementary.

Summary In diabetes, (1) endocrine identity recapitulates the less mature/less-differentiated fetal/neonatal cell type, possibly representing an adaptive mechanism; (2) residual β cells may be altered in their subtype proportions or other molecular features; (3) in humans, “altered identity” is a preferable term to dedifferentiation as their cellular fate (differentiated cells losing identity or progenitors becoming more differentiated) is unclear as yet.

Keywords β Cell · Dedifferentiation · Transdifferentiation · Type 1 diabetes · Type 2 diabetes · Pancreas

Introduction

Both classic forms of diabetes mellitus are characterized by the inability of pancreatic β cells to meet the demand of insulin secretion due to either a nearly complete loss (type 1 diabetes [T1D]) or a deficit of functional β cells in the setting of

peripheral insulin resistance (type 2 diabetes [T2D]). The deficit in β cell mass (~90% in long-standing T1D [1], ~65% in long-standing T2D [2]) has long been proposed to be a consequence of β cell death. However, this principle has recently been challenged by studies mainly performed in animal models, with the suggestion that, rather than β cell death, the deficit in β cell mass is due to β cell dedifferentiation or transdifferentiation [3•, 4].

Functional β cell mass refers to adequate numbers of appropriately functioning β cells; a deficit in either number or function/identity can therefore lead to a diminution of “functional β cell mass” [5, 6]. Altered β cell identity, rather than β cell apoptosis, in the setting of chronic hyperglycemia was first reported in Sprague-Dawley rats [7]. Subsequently, others reported a loss of mature β cell identity accompanied by dedifferentiation in the diabetic state [3, 8•, 9•, 10•]. Upon dedifferentiation, β cells regress to a less mature or even precursor-like state, leading to a loss of key components

This article is part of the Topical Collection on *Pathogenesis of Type 1 Diabetes*

✉ Alexandra E. Butler
abutler@hbku.edu.qa

Abu Saleh Md Moin
amoin@hbku.edu.qa

¹ Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, PO Box 34110 Doha, Qatar

responsible for optimal performance, most notably in terms of insulin secretion. However, there is ambiguity in defining “dedifferentiation,” as altered β cell identity can also be explained as “ β cell degranulation,” where insulin granules are depleted due to metabolic stresses [9•, 11]. Emerging evidence also suggests that phenotypic alterations of β cells can promote transdifferentiation to other pancreatic endocrine cell types (mainly α cells and δ cells), a phenomenon that has been observed in both diabetic animals and human subjects [4, 9•, 10•, 12, 13]. Regardless of how β cell dedifferentiation is defined, its importance in diabetes research stems from the direct implications for β cell function, turnover, and regeneration. In this review, we will discuss the characteristics of human pancreatic β cells, the concept of “ β cell identity-crisis,” and the factors underlying the altered identity of β cells in diabetes.

Fetal Development of Human Endocrine Pancreas: the Transcriptional Roadmap of Human β Cell Differentiation

The organogenesis of human pancreas involves regulation at the level of gene transcription to furnish mature pancreatic cells. Originating from a pool of apparently identical progenitor cells, the mature pancreas comprises endocrine, exocrine, and ductal cell types that collectively synthesize and secrete the hormones and enzymes required for nutritional homeostasis [14]. The endocrine compartment (Islets of Langerhans) further differentiates into five cell types (α , β , δ , PP, ϵ) that have obvious similarities in expression of common genes and ability to secrete hormones [14]. In comparison to rodent pancreas, the knowledge of gene expression profiles during early human pancreas development is limited. However, several studies suggest the involvement of conserved genetic regulatory networks and transcription factors [14–16].

The pancreas originates from two primary diverticula of the primitive gut at 26-day post-conception (dpc; ~6-week gestation) [15]. After gastrulation, the earliest event leading to pancreas development is exclusion of sonic hedgehog (SHH) signaling from the dorsal endoderm where it is in contact with the notochord [17], which allows expression of the key transcription factor pancreatic and duodenal homeobox factor 1 (PDX1) [18, 19]. The gut epithelium evaginates into the surrounding mesoderm-derived mesenchymal tissue from the dorsal and ventral pancreatic buds, which at Carnegie stage 13 (CS13, ~6.5-week gestation) in humans is marked by the transcription factors SRY (sex determining region Y)-box 9 (SOX9), PDX1, and GATA binding protein 4 (GATA4) [14, 15]. The buds expand, branch, and fuse, and, by CS15 (~7.5-week gestation), gut rotation brings the buds together on either side of the portal vein [14, 20], the ventral portion giving rise to the lower head of the pancreas and the dorsal portion giving

rise to the body, tail, and upper head portion of pancreas. Between CS15 and CS19, the central duct-like structure (“trunks”) contains a pool of multipotent progenitor cells that express more SOX9/NKX6.1 but less GATA4, whereas the more peripheral clustered cells (“tips”) are triple-positive (SOX9/GATA4/NKX6.1) [14]. By CS19 (~9-week gestation), the pancreatic progenitor cells become more differentiated, with segregation of acinar and endocrine precursors.

Endocrine pancreas formation requires the transient activation of Neurogenin3 (NEUROG3), as NEUROG3⁺ cells generate the five endocrine cell subtypes. NEUROG3 expression increases rapidly during late embryogenesis and is closely linked to the appearance of fetal insulin (CS20–21) (~9–10-week gestation) [14]. Fetal β cells demonstrate a unique transcription factor signature (for example, loss of SOX9) with subsequent detection of nuclear NKX2.2, NKX6.1, PDX1, FOXA2, ISL1, and insulin [14]. Co-expression of several hormones is notable amongst endocrine cells in the developing human pancreas. Polyhormonal cells are typically present either as single cells or in small clusters in the acinar parenchyma, suggesting that these cells represent newly forming islets [21–23].

Formation of secretory granules with an increase in insulin content occurs in β cells at ~10–14-week gestation [24], a concept supported by the expression of more differentiated β cell markers (PC1/3, IAPP) in virtually all β cells at 12–14 weeks of development [15, 25]. Data from previous studies suggests that large islets of mixed types (akin to adult islets) are formed only after 21-week gestation [21] and are accompanied by increased numbers of β cells, produced by β cell proliferation, thereby increasing the β/α and β/δ cell ratios [26]. After birth, the human pancreatic β cell proliferation index is highest during the first 2 years, gradually decreasing until, after the age of 3–5 years, replication of existing β cells is negligible in most cases [27].

Postnatal Distribution and Identity of Mature β Cells

To study β cell dedifferentiation, it is important to understand how pancreatic β cells are organized in the complex cytoarchitecture of an islet (reviewed in [28]). Detailed quantitative studies have revealed that human pancreatic islets consist of ~60% insulin-producing β cells and 30% glucagon-producing α cells, the remaining 10% consisting of δ cells (somatostatin), γ cells (PP) and ϵ cells (ghrelin) [29–31] randomly distributed throughout the islet [32, 33]. Exactly how this architecture affects cell-to-cell interactions leading to regulated and concerted hormonal secretion remains to be determined; however, a modified core-mantle structure of the human islet has been proposed where, in small human islets (40–60 μm in diameter), β cells are in the core position surrounded

by α cells in the mantle position, with a more complex intermingled arrangement found in larger islets [34]. Similar studies also reported that β cells are contiguously arranged either into smaller clusters surrounded by non- β cells or along invaginations of the exterior surface of the islet [35, 36]. An alternative arrangement of β cells in human islets has also been described with β cells intermingling freely (without clustering) with other endocrine cells [30]. The unique topological arrangements of β cells (especially β - β cell contacts) in human islets has measurable consequences in terms of islet function [37, 38]. In addition to intra-islet connections, individual human β cells and larger aggregates of cells (in association with the mesenchymal protein vimentin) can form within the ductal epithelium and migrate during gestation, suggesting that β cells are capable of remodeling [39]. In humans, β cells harbor connexin-36 (Cx36) gap junctions that create channel coupling between β cells, and which correlate with insulin secretion, suggesting the dependence of functional identity of human β cells on gap junction coupling [40].

A β cell is classically defined by its function: synthesizing, sorting, and secreting insulin. However, the hallmark of a mature β cell involves a more complex cellular identity with finely tuned coupling to the prevailing glucose level. Ultrastructurally, β cells are marked by the presence of electron dense-core insulin granules with a clear peripheral mantle (size, \sim 300 nm and number, \sim 10,000 per β cell). The presence or absence of fully processed proinsulin molecules in these dense-core granules depends on the maturity of the β cell [41–43]. As previously noted, the fate of islet endocrine cells is decided by the ON/OFF switch and concerted activities of key transcription factors during development; mature β cells are also distinct in terms of expression of certain genes and transcription factors. Single-cell analyses that have revealed the transcriptional program of human pancreatic endocrine cells depicted genes (for example, PAX4, PDX1, MAFA, MAFB, DLK1, SIX2/3, ID1, IAPP, UCN3, OLIG1) that are highly or exclusively expressed in human β cells ([44•] and reviewed in [45]). Expression of certain genes has revealed notable cell-type and species differences. For example, in humans, MAFB expression has been detected in adult α and β cells [44•, 46•], whereas MafB and MafA expressions become restricted to α and β cells, respectively, in the mouse [47, 48]. In addition, SIX2 and SIX3, two recently identified transcription factors reported in human β cells [46•, 49, 50•], have been shown to enhance insulin content and secretion in immature β cells, suggesting their crucial role in human β cell maturation [51].

Heterogeneity of β cells has recently received increasing attention, as emerging evidence (mainly from rodent studies) suggests that β cells pass through different maturation states in adult islets [52•, 53•]. During development, distinct subpopulations of β cells have been observed [54, 55•]. In adult human islets, marker analysis coupled with single-cell RNA

sequencing (scRNA-seq) revealed two surface markers, ST8SIA1 and CD9, that discriminated four distinct human β cell subpopulations (β 1–4), each expressing common β cell markers but displaying differences in insulin secretion rates and gene expression profiles [56•]. It is however uncertain whether in adults these subsets are proportionally stable or whether they can interconvert. A population of β cells has been shown to develop during the progression of T1D in non-obese diabetic (NOD) mice which have characteristics of immature proliferation, reduced insulin granule content, and reduced functional capacity with relative resistance to cell death [57]. In T2D, three distinct subpopulations of β cells were identified, shifting in number with age or BMI [58•], suggesting a possible correlation of β cell heterogeneity and dysfunction in diabetes and aging, due partly to altered phenotypes of human β cells in islets. Apart from the molecular heterogeneity, functional heterogeneity within the β cell population also exists which might offer advantages for the ability of β cells to respond robustly to different physiological conditions. For example, by utilizing a set of novel techniques, insulin secretion responses were found to be orchestrated by two populations of β cells in rodents: the hub cells, which function as pacemakers to control the insulin secretion dynamics, and the follower cells that respond to hub cell signaling cues [59•]. More detailed molecular characterizations of subgroups of β cells are required to determine their biological significance, function, ontogeny, and involvement in disease. The main challenge in this regard is the high donor-to-donor variation identified by single-cell studies [46, 52•, 58•]; however, a recently developed single-cell heterogeneity analysis algorithm (RePACT) might help to resolve these issues and to identify β cell specific disease genes [60•].

β Cell turnover is a critical factor for maintaining functional β cell mass in health. Postnatal β cell mass is dynamic and maintained by the balance of cell birth/renewal (by replication of pre-existing differentiated β cells and by neogenesis or differentiation from progenitor cells) and cell death (usually by apoptosis) [27, 61]. Though adult β cells are largely in a quiescent state (evidenced by a very low frequency of proliferation) [27], β cell mass demonstrates a degree of plasticity, expanding in response to metabolic demands associated with the insulin resistance of pregnancy [62] and obesity [2]. The establishment of β cell mass during childhood likely plays a crucial role in successful or failed adaptation to increased β cell metabolic workload demand, a key factor for the onset of T2D [63, 64].

Dedifferentiation of Pancreatic β Cells—Altered Identity

Dedifferentiation of a cell is determined by either a reversal of the differentiation signature back towards a progenitor-like state or loss of terminally differentiated markers and

phenotype [65, 66]. β Cell dedifferentiation, however, is a broad and loosely defined term that generally refers to an alteration in β cell phenotype. β Cell dedifferentiation was first reported in rats where prolonged exposure to hyperglycemia correlated with progressive loss of β cell differentiation (as determined by altered expression of several key islet transcription factors and other islet genes important for normal glucose-stimulated insulin secretion [GSIS]) [7]. Further studies in rodents and humans indicated that β cell dedifferentiation manifests as reduced expression of β cell-enriched genes [65, 66]; gradual loss of β cell specific transcription factors including PDX1, MAFA, and FOXO1 [6, 67, 68]; and re-occurrence of endocrine progenitor markers (NGN3 and OCT4 [3] or ALDH1 [9], for example). These alterations cause β cells to undergo metabolic and structural reconfiguration, exiting their mature state (“failing β cells”) and ultimately results in defective GSIS (Fig. 1a). What remains undetermined is whether these failing β cells can re-differentiate back into a mature state, remain as dedifferentiated cells with poor ability to secrete insulin in response to glucose, or, alternatively, whether β cell death is inevitable. Therefore, the importance of β cell dedifferentiation stems from the fact that, along with phenotypic cellular changes, there is diminution of the cell’s ability to optimally respond to a glucose challenge with insulin secretion. Dysregulated insulin secretion ensues a well-recognized phenomenon in the pathogenesis of both T1D and T2D, and, together with the established mechanism of β cell apoptosis [2, 69], β cell dedifferentiation has been proposed as a factor in the loss of functional β cells in T1/T2D. [3, 9, 11].

Transdifferentiation of Pancreatic β Cells—Altered Identity Continued

Transdifferentiation refers to the process, whereby a mature endocrine cell transforms into another cell type without reverting backwards towards a more primitive progenitor-like state. Only a few examples of transdifferentiation of human cells have been reported to date, and those require forced expression of transcription factors or miRNAs for the conversion of human fibroblasts into neurons, hematopoietic progenitors, or brown fat cells [70] or of human liver cells into β cells [71]. Even though mature human β cells are considered as “non-switching” in terms of their hormone production, spontaneous conversion of human β cells into glucagon producing α cells has been reported during islet cell reaggregation in vitro [4]. These results are consistent with other reports where, in both T1D and T2D, β cells transdifferentiated into α cells in humans [10, 72] or into δ cells in rats [73] and mice [13].

Various mouse models of diabetes have also revealed that a percentage of existing β cells can adopt the mature identity of glucagon-producing α cells under hyperglycemic conditions

[3, 12]. While it has not been firmly established, it appears that loss of β cell mass/function is the driving force towards this seemingly counterintuitive change. Insulin may be required to maintain β cell identity, a reduction in insulin release in the local islet environment potentially having an impact upon the identity of endocrine cells. Inappropriately increased α cell function and consequent hyperglucagonemia has long been recognized as a contributor to hyperglycemia in diabetic patients, via stimulation of hepatic glucose production [74]; therefore, stringent control over β to α -transdifferentiation (by minimizing β cell plasticity) might be helpful in preventing the progression of diabetes. Transdifferentiation of pancreatic α to β cells has also been reported in a mouse model where over-expression of PAX4 [75] or deletion of *Arx* [76, 77] in α cells resulted in loss of α cells through transdifferentiation to β cells. These data suggest potential new avenues for restoration of β cell mass in diabetes, not only by providing alternative sources of β cells, but also by reducing α cell mass, and thus potentially restoring the insulin-glucagon balance, which is perturbed in diabetes [78, 79]. Apart from α to β transdifferentiation, the regenerative process of endocrine pancreas also includes transdifferentiation of pancreatic ductal cells to endocrine β cells in rodents. By utilizing a genetic lineage-tracing approach (a mouse model used to trace the ductal specific human carbonic anhydrase-II (CA-II)-positive cells in which the CA-II promoter is conjugated with the *Cre-Loxp* system) showed that CA-II-positive cells merged with β cells in the adult pancreas and ligated duct, suggesting a potential transdifferentiation of ductal cells to generate new islets [80]. Moreover, the existence of rat and human pancreatic progenitor cells in the duct and their differentiation potentials has also been reported [81, 82]. The regenerative capacity of endocrine pancreas from ductal sources is also supported by our recent report showing an increased proliferation of the pancreatic duct gland (PDG) compartment in humans with T1D [83].

Altered Identity of Pancreatic β Cells in Humans with T1D and T2D—Are β Cells Hidden or Camouflaged?

Circumstantial evidence of an altered β cell phenotype in clinical diabetes was revealed by the observation of co-localization of insulin with glucagon or vimentin (a mesenchymal marker) in a distinct subset of cells in human pancreas sections from subjects with T2D [84, 85]. Likewise, a significant increase in bihormonal insulin⁺/glucagon⁺ and NKX6.1⁺/amyloid⁺/glucagon⁺ cells was found upon analysis of mature β cell markers (e.g., MAFA, FOXO1, NKX6.1) in T2D human and nonhuman primate pancreas [10]; a greater frequency of Nkx6.1⁺ glucagon⁺ insulin⁻ cells was found in islet amyloid-positive regions.




Fig. 1 **a** A schematic illustrating the possible “altered differentiation” states of human pancreatic β cells. In response to cellular stresses (glucotoxicity, ER stress, immune attack or viral infection), β cells can undergo functional or morphological changes. These alterations might include insulin-positive dysfunctional β cells or insulin-negative β cells that are dedifferentiated (expressing transcription factors of endocrine progenitor cells), degranulated (“empty” β cells no longer harboring a normal complement of insulin granules), or transdifferentiated (transitioning towards a different endocrine cell subtype). At this stage, the β cells may be recognized as “failing β cells,” as they do not contain any releasable insulin. The unanswered questions are whether human β cells from those transition states can revert back towards the mature, fully functional state, or whether they will eventually fail completely and undergo apoptotic death. **b** Example of chromograninA-positive

hormone-negative (CPHN) cells in the pancreas of a lean subject with type 2 diabetes (Age, 70 years, BMI, 24.3). The merged immunofluorescent image is a selected field of 4- μ m paraffin section of pancreas stained for insulin (white), endocrine cocktail (glucagon, somatostatin, pancreatic polypeptide and ghrelin) (green), chromograninA (ChgA) (red), and DAPI (blue). The cells staining only for chromograninA and not for any of the known pancreatic hormones (CPHN cells) are therefore stained red (and indicated by yellow arrows). Inset, high-power image of the selected area (marked by white square in the low power image) indicating the CPHN cells. Scale bar, 50 μ m. **c** Percent of β cells and CPHN cells (of total endocrine cells) in lean human subjects with no diabetes (LND) and lean human subjects with type 2 diabetes (LT2D). Data are presented as mean \pm SEM, $N=10$ (each group). *, $p < 0.01$

An altered phenotype in islets from subjects with T2D was observed with an ~3-fold increase in the number of pancreatic islet cells (insulin⁻/synaptophysin⁺/ALDH1A3⁺ cells) that no longer expressed any of the major pancreatic hormones, yet retained endocrine features, thus implying dedifferentiation of β cells in T2D [9]. Moreover, in T2D, human β cells were found to express gastrin (an embryonic pancreas marker), a phenotype that resolved upon glucose normalization, suggesting reversible β cell reprogramming in T2D [55, 86].

We first reported an increased frequency of endocrine cells that express no known islet hormones but do express the endocrine marker chromograninA (chromogranin A-positive

hormone-negative [CPHN cells]) in humans with T1D [87••, 88] and T2D [8••, 89••] (Fig. 1b). CPHN cells occurred within established islets but were most frequently found as scattered cells, either singly or in small clusters in the exocrine pancreas. Despite the lack of expression of any endocrine hormones in CPHN cells in T1D, the presence of β cell-specific transcription factors (for example, NKX6.1 and NKX2.2) found mainly in the scattered or single cells suggested that those cells represent a pool of “hidden β cells” [87••]. While it is potentially plausible that these cells were formerly β cells that have undergone dedifferentiation or transdifferentiation, this is less likely given their distribution and increased frequency as

scattered cells in exocrine pancreas in the setting of diabetes; it is therefore possible that they represent partially differentiated, newly formed endocrine cells. In support of this, we further reported abundant scattered CPHN cells in the exocrine compartment of human fetal and neonatal pancreas [8••], the highest frequency being in fetal pancreas compared to neonatal [90], potentially suggesting that the increased frequency of CPHN cells containing the β cell-specific transcription factors NKX6.1 or NKX2.2 in both T1D and T2D may be indicative of attempted β cell regeneration.

This conclusion is consistent with previous findings where pancreatic β cell regeneration in humans with recent-onset T1D was reported [91, 92]. Moreover, persistent residual β cell function in patients with recent-onset or, in some cases, very long-standing T1D has been reported [93–95], with measurable levels of C-peptide detected in serum of donors with long-standing T1D [96•, 97••]. To date, it has not been possible to trace the β cell lineage in those individuals to determine if their residual β cells had (1) dedifferentiated, evaded immune attack, and then redifferentiated again (perhaps once insulin therapy had been initiated) [98]; (2) transdifferentiated from other endocrine cells; or (3) are newly generated β cells in a transition state towards maturity. Whether due to loss of identity or attempted regeneration, the altered endocrine phenotype in T1D/T2D likely reflects an adaptive response (either to camouflage the endocrine cells from potential destruction or to expand/regenerate).

One approach to establish the sequence of events leading to defective β cell function and mass in diabetes is to evaluate the pancreas from prediabetic individuals. However, there was no change in the frequency of CPHN cells in pancreas from nondiabetic autoantibody-positive brain dead organ donors (unpublished data); however, most of these donors had a single autoantibody to a T1D autoantigen, which is associated with low risk of progression to clinical diabetes in living subjects, and they did not have evidence of insulinitis or beta cell destruction. Perhaps it would be more instructive to study pancreas from double or triple antibody-positive prediabetic donors to elucidate the pattern of endocrine cell identity alterations in incipient diabetes; these donors are, however, quite rare [99••].

Whilst the evidence reported in the literature from numerous sources supports the concept that dedifferentiation or transdifferentiation of β cells does occur in T1D and T2D, one critical question is to what extent? We found ~3% increase in $\text{Ins}^+/\text{Glu}^+$ bihormonal cells in the pancreas in subjects with T2D with a further increase to about 16% in incretin-treated individuals with T2D [85]. This ~3–4% frequency in T2D was later confirmed [10••]. To address the quantitative contribution of altered β cell identity to the β cell deficit, we studied the frequency of polyhormonal cells and determined that changes of β cell identity that have been ascribed to loss of differentiation in T2D could only account for approximately 2% of β cell loss

(Fig. 1c) [89••]. In addition, our data revealed an increased frequency of polyhormonal cells ($\text{Ins}^+/\text{hormone cocktail}^+$ cells) in lean subjects with T2D [89••]. Given that human pancreas, obtained at the time of surgery or at post-mortem, is by definition a single timepoint for any given individual, it is not possible to definitively determine the evolution and fate of those “camouflaged” Ins^+ β cells in humans with T2D.

Mechanisms Involved in β Cell Dedifferentiation in T1D and T2D

The exact mechanisms of pancreatic β cell dedifferentiation in humans with T1D or T2D is yet to be elucidated (potential drivers of the β cell dedifferentiation in T1D and T2D are listed in Table 1). Our cross-sectional study in pancreas of humans with T1D demonstrated no T cell infiltration (as adjudged by staining for the presence of CD45) in or around hormone-negative endocrine cells, suggesting that direct interaction of autoimmune T cells with β cells might not be responsible for alterations in β cell identity in humans with T1D; however, it is also possible that CPHN cells are not yet expressing surface antigens that attract autoimmune T cells [87••]. In a different setting of pancreatic pathogenesis, where inflammation plays a central role, we reported increased co-expression of islet-derived chemokine (CXCL10) and chemokine receptor (CXCR3) in $\text{Ins}^+/\text{Glu}^+$ double-positive cells in humans with chronic pancreatitis [111].

Islet-derived proinflammatory mediators might induce β cell dedifferentiation in human T1D, as the islet microenvironment has also been reported to be the generator of proinsulin targeting CD4 T cells in humans with T1D [100]. Such impaired “self-maintenance” of pancreatic β cells has also been observed in T2D, where cytokines and chemokines (secreted by β cells) recruit macrophages by inducing stress signaling in islets [101], and this may ultimately play a role in “inflammation-induced dedifferentiation” in T2D [102••]. The molecular mechanism of such β cell decompensation is not known, however though, factors such as microRNAs [103] or virus-like infection (enteroviral infection) [107] might be key regulators of this process.

Extensive animal and in vitro studies have implicated glucotoxicity and dysregulation of downstream pathways as being involved in β cell dedifferentiation. Cellular events, like hyperglycemia-induced alterations of β cell-specific gene expression (for example, downregulation of β cell-enriched genes and upregulation of β cell “forbidden” genes) (extensively reviewed in [112••]), might lead to the altered phenotypic and functional changes that are the hallmarks of a dedifferentiated β cell. Despite the fact that high glucose levels, as well as the duration of hyperglycemia, are two major upstream regulators of β cell dedifferentiation, our experimental data has demonstrated that the increase in both CPHN cells and polyhormonal endocrine cells in the human

Table 1 Drivers of altered identity of β cells in T1D and T2D

Cellular and physiological modulators	Altered identity of β cells in		Most relevant references
	T1D	T2D	
Hyperglycemia	Documented	Documented	[3••, 7, 9••, 10••, 11••, 87]
Inflammation	Possibly linked	Documented	[100–102]
Obesity	Possibly linked, (no direct evidence)	Documented	[8••]
miRNA	Possibly linked (no direct evidence)	Possibly linked	[103]
Epigenetics	Possibly linked	Possibly linked	[104••, 105•, 106•]
Beta cell heterogeneity	Documented	Documented	[57, 58]
Viral infection	Possibly linked	Possibly linked (no direct evidence)	[107]
Protein misfolding/ER stress	Possibly linked	Possibly linked	[108–110]

IAPP-transgenic (HIP) rat (a model of T2D) is already present by 2–3 months of age, thereby preceding diabetes onset, elevations in glucose, or any measurable loss of β cell mass [89]. This implies that β cell stressors, in the HIP rat consequent upon IAPP mis-folding and cell dysfunction induced by IAPP-derived toxic oligomers, provoke the alteration in β cell identity and the increase in CPHN cells, rather than the hyperglycemia that develops only from the age of 5 months in this model [113]. Peptide-based analyses of epitope targeting by either CD4 or CD8 T cells revealed a plausible role of IAPP as an autoantigen in the pathophysiology of T1D both in humans and in a non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes [114–117]. Recently, histological studies on pancreas from subjects with recent onset T1D have revealed that amyloidosis is also present in T1D [118, 119•].

Endoplasmic reticulum (ER) stress with inadequate induction of an adaptive unfolded protein response (UPR) might be a key driver of β cell dedifferentiation. β Cells are extremely dependent on their ER to cope with the oscillatory requirement of secreted insulin to maintain normoglycemia. Altered metabolic states, for example in obesity, result in decreased insulin sensitivity in the skeletal muscle, liver, and adipose tissues that is counteracted by a compensatory increase in insulin secretion by β cells through an increase in both β cell function and mass [120]. For insulin translation and folding, β cells rely greatly on the unfolded protein response (UPR), an array of three main signaling pathways designed to maintain ER homeostasis and limit ER stress [121]. A recent study demonstrated that targeted deletion of ATF4 (the main transcriptional regulator of UPR) in β cells in Akita mice (*Akita/ β ATF4KO*) leads to the increase in number of glucagon, somatostatin, or pancreatic polypeptide-positive cells in islets, suggesting increased β cell dedifferentiation [108]. Therefore, the fine-tuning of this adaptive UPR is vital for the preservation of the β cell differentiated phenotype and failure of this process is associated with the progression to diabetes and altered β cell differentiation [109, 110].

Epigenetic regulation of pancreatic β cell identity could also play a crucial role in maintaining β cell plasticity. For example, the α cell-specific DNA-binding protein *Arx* must be repressed to prevent β - to α -transdifferentiation in a mouse model [122]. *Arx* silencing in β cells is accomplished, at least in part, by binding of the transcription factor Nkx2.2 to the *Arx* promoter, followed by recruitment of DNA methyltransferase Dnmt3, increased DNA (CpG) methylation, and finally binding of MeCP2, a DNA-binding protein, to the promoter region of *Arx* in β cells to establish and maintain a fully repressed state [104••, 123]. Recently, unbiased epigenome mapping and single-cell RNA sequencing (ScRNA-Seq) have revealed that the β cell-specific chromatin regulatory system, Polycomb (Eed/PRC2), is necessary for maintenance of global silencing and terminal differentiation of β cells in the mouse [105•]. Therefore, as observed in rodent models of diabetes [55], it is likely that epigenetic dysregulation similarly contributes to β cell dedifferentiation in humans with T1D or T2D [106•].

Concluding Remarks and Future Perspectives

Pancreatic β cell dedifferentiation encompasses both a loss of one or more elements that are present in a mature functional β cell (this occurring for a multitude of reasons, including cellular stress or senescence) and a regression back towards a more primitive state, such as the pluripotent progenitor cell from whence it came.

Emerging evidence suggests that altered β cell identity in humans with T1D and T2D contributes to impaired β cell function in diabetes; however, the exact mechanisms are not known. Such cellular adoption of a resting or dedifferentiated state for a subset of pancreatic β cells might be a natural phenomenon that temporarily allows interruption of regular cellular function, serving as a protective mechanism to circumvent damage or death.

In order to derive benefits from the inherent plasticity of pancreatic β cells in humans with T1D or T2D, future research should aim to enhance our understanding of some key questions. Firstly, the extent of altered β cell identity in humans with prediabetes is yet to be determined, and this knowledge would be instructive in characterizing β cell dedifferentiation in humans. Secondly, it is imperative to identify key regulatory molecules and molecular markers of β cell dedifferentiation in humans (possibly by using laser capture microdissection of the altered β cell followed by single-cell RNA-seq). Thirdly, it is crucial to understand how the expression of chromograninA remains unaltered in the dedifferentiated β cell, given that insulin and chromograninA reside in the same dense-core granules of the β cell. Finally, effective re-differentiation mechanisms directed towards “altered state” pancreatic β cells should be explored, as identifying ways to inhibit or reverse these stages could substantially enhance the scope for developing novel therapies for restoration of β cell function in diabetes.

Funding Information Open Access funding provided by the Qatar National Library.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? *Diabetologia*. 2005;48(11):2221–8. <https://doi.org/10.1007/s00125-005-1949-2>.
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes*. 2003;52(1):102–10.
3. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. *Cell*.

- 2012;150(6):1223–34. <https://doi.org/10.1016/j.cell.2012.07.029>. **This is the first report where β cell dedifferentiation was proposed as an alternative mechanism in animal model of T2D.**
4. Spijker HS, Ravelli RB, Mommaas-Kienhuis AM, van Apeldoorn AA, Engelse MA, Zaldumbide A, et al. Conversion of mature human beta-cells into glucagon-producing alpha-cells. *Diabetes*. 2013;62(7):2471–80. <https://doi.org/10.2337/db12-1001>.
5. Pipeleers D, Chintinne M, Denys B, Martens G, Keymeulen B, Gorus F. Restoring a functional beta-cell mass in diabetes. *Diabetes Obes Metab*. 2008;10(Suppl 4):54–62. <https://doi.org/10.1111/j.1463-1326.2008.00941.x>.
6. Guo S, Dai C, Guo M, Taylor B, Harmon JS, Sander M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. *J Clin Invest*. 2013;123(8):3305–16. <https://doi.org/10.1172/JCI65390>.
7. Jonas J-C, Sharma A, Hasenkamp W, Ilkova H, Patanè G, Laybutt R, et al. Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes. *J Biol Chem*. 1999;274(20):14112–21. <https://doi.org/10.1074/jbc.274.20.14112>.
8. Butler AE, Dhawan S, Hoang J, Cory M, Zeng K, Fritsch H, et al. Beta-cell deficit in obese type 2 diabetes, a minor role of beta-cell dedifferentiation and degranulation. *J Clin Endocrinol Metab*. 2016;101(2):523–32. <https://doi.org/10.1210/jc.2015-3566>. **This report demonstrated that dedifferentiated β cells played minor role in β cell deficit in human with T2D.**
9. Cinti F, Bouchi R, Kim-Muller JY, Ohmura Y, Sandoval PR, Masini M, et al. Evidence of beta-cell dedifferentiation in human type 2 diabetes. *J Clin Endocrinol Metab*. 2016;101(3):1044–54. <https://doi.org/10.1210/jc.2015-2860>. **Evidence of β cell dedifferentiation and transdifferentiation in human with T2D.**
10. Spijker HS, Song H, Ellenbroek JH, Roefs MM, Engelse MA, Bos E, et al. Loss of beta-cell identity occurs in type 2 diabetes and is associated with islet amyloid deposits. *Diabetes*. 2015;64(8):2928–38. <https://doi.org/10.2337/db14-1752>. **This report revealed a possible association of toxic islet amyloid polypeptide (IAPP) in β cell dedifferentiation in human with T2D.**
11. Marselli L, Suleiman M, Masini M, Campani D, Bugliani M, Syed F, et al. Are we overestimating the loss of beta cells in type 2 diabetes? *Diabetologia*. 2014;57(2):362–5. <https://doi.org/10.1007/s00125-013-3098-3>.
12. Brereton MF, Iberl M, Shimomura K, Zhang Q, Adriaenssens AE, Proks P, et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. *Nat Commun*. 2014;5:4639. <https://doi.org/10.1038/ncomms5639>.
13. Piran R, Lee SH, Li CR, Charbono A, Bradley LM, Levine F. Pharmacological induction of pancreatic islet cell transdifferentiation: relevance to type I diabetes. *Cell Death Dis*. 2014;5:e1357. <https://doi.org/10.1038/cddis.2014.311>.
14. Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, et al. Development of the human pancreas from foregut to endocrine commitment. *Diabetes*. 2013;62(10):3514–22. <https://doi.org/10.2337/db12-1479>.
15. Piper K, Brickwood S, Turnpenny LW, Cameron IT, Ball SG, Wilson DI, et al. Beta cell differentiation during early human pancreas development. *J Endocrinol*. 2004;181(1):11–23.
16. Jennings RE, Berry AA, Strutt JP, Gerrard DT, Hanley NA. Human pancreas development. *Development*. 2015;142(18):3126–37. <https://doi.org/10.1242/dev.120063>.
17. Hebrok M, Kim SK, Melton DA. Notochord repression of endodermal Sonic hedgehog permits pancreas development. *Genes Dev*. 1998;12(11):1705–13.
18. Jorgensen MC, Ahnfelt-Ronne J, Hald J, Madsen OD, Serup P, Hecksher-Sorensen J. An illustrated review of early pancreas

- development in the mouse. *Endocr Rev.* 2007;28(6):685–705. <https://doi.org/10.1210/er.2007-0016>.
19. Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to gland. *Dev Dyn: an official publication of the American Association of Anatomists.* 2011;240(3):530–65. <https://doi.org/10.1002/dvdy.22584>.
 20. Puri S, Hebrok M. Cellular plasticity within the pancreas—lessons learned from development. *Dev Cell.* 2010;18(3):342–56. <https://doi.org/10.1016/j.devcel.2010.02.005>.
 21. Jeon J, Correa-Medina M, Ricordi C, Edlund H, Diez JA. Endocrine cell clustering during human pancreas development. *J Histochem Cytochem : official journal of the Histochemistry Society.* 2009;57(9):811–24. <https://doi.org/10.1369/jhc.2009.953307>.
 22. Jensen J, Heller RS, Funder-Nielsen T, Pedersen EE, Lindsell C, Weinmaster G, et al. Independent development of pancreatic alpha- and beta-cells from neurogenin3-expressing precursors: a role for the notch pathway in repression of premature differentiation. *Diabetes.* 2000;49(2):163–76.
 23. Kaligin MS, Gumerova AA, Titova MA, Andreeva DI, Sharipova EI, Kiiasov AP. C-kit is a marker of human pancreatic endocrinocyte stem cells. *Morfologiya.* 2011;140(4):32–7.
 24. von Dorsche HH, Falkmer S. Ontogeny of human Langerhans Islets. A review of some light- and electron- microscopical, immunohistochemical and functional data on fetal development of the endocrine pancreas. *J Evol Biochem Physiol.* 2000;36(6):701–18.
 25. Wilson ME, Kalamaras JA, German MS. Expression pattern of IAPP and prohormone convertase 1/3 reveals a distinctive set of endocrine cells in the embryonic pancreas. *Mech Dev.* 2002;115(1–2):171–6.
 26. Gregg BE, Moore PC, Demozay D, Hall BA, Li M, Husain A, et al. Formation of a human beta-cell population within pancreatic islets is set early in life. *J Clin Endocrinol Metab.* 2012;97(9):3197–206. <https://doi.org/10.1210/jc.2012-1206>.
 27. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. *Diabetes.* 2008;57(6):1584–94. <https://doi.org/10.2337/db07-1369>.
 28. Nair G, Hebrok M. Islet formation in mice and men: lessons for the generation of functional insulin-producing beta-cells from human pluripotent stem cells. *Curr Opin Genet Dev.* 2015;32:171–80. <https://doi.org/10.1016/j.gde.2015.03.004>.
 29. Ionescu-Tirgoviste C, Gagniuc PA, Gubceac E, Mardare L, Popescu I, Dima S, et al. A 3D map of the islet routes throughout the healthy human pancreas. *Sci Rep.* 2015;5:14634. <https://doi.org/10.1038/srep14634>.
 30. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. *Proc Natl Acad Sci U S A.* 2006;103(7):2334–9. <https://doi.org/10.1073/pnas.0510790103>.
 31. Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. *J Histochem Cytochem : official journal of the Histochemistry Society.* 2005;53(9):1087–97. <https://doi.org/10.1369/jhc.5C6684.2005>.
 32. Kim A, Miller K, Jo J, Kilimnik G, Wojcik P, Hara M. Islet architecture: a comparative study. *Islets.* 2009;1(2):129–36. <https://doi.org/10.4161/isl.1.2.9480>.
 33. Steiner DJ, Kim A, Miller K, Hara M. Pancreatic islet plasticity: interspecies comparison of islet architecture and composition. *Islets.* 2010;2(3):135–45.
 34. Bosco D, Armanet M, Morel P, Niclauss N, Sgroi A, Muller YD, et al. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. *Diabetes.* 2010;59(5):1202–10. <https://doi.org/10.2337/db09-1177>.
 35. Brelje TC, Scharp DW, Sorenson RL. Three-dimensional imaging of intact isolated islets of Langerhans with confocal microscopy. *Diabetes.* 1989;38(6):808–14.
 36. Weir GC, Bonner-Weir S. Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes. *J Clin Invest.* 1990;85(4):983–7. <https://doi.org/10.1172/jci114574>.
 37. Halban PA, Wollheim CB, Blondel B, Meda P, Niesor EN, Mintz DH. The possible importance of contact between pancreatic islet cells for the control of insulin release. *Endocrinology.* 1982;111(1):86–94. <https://doi.org/10.1210/endo-111-1-86>.
 38. Jaques F, Jousset H, Tomas A, Prost AL, Wollheim CB, Irrminger JC, et al. Dual effect of cell-cell contact disruption on cytosolic calcium and insulin secretion. *Endocrinology.* 2008;149(5):2494–505. <https://doi.org/10.1210/en.2007-0974>.
 39. Cole L, Anderson M, Antin PB, Limesand SW. One process for pancreatic beta-cell coalescence into islets involves an epithelial-mesenchymal transition. *J Endocrinol.* 2009;203(1):19–31. <https://doi.org/10.1677/joe-09-0072>.
 40. Serre-Beinier V, Bosco D, Zulianello L, Charollais A, Caille D, Charpentier E, et al. Cx36 makes channels coupling human pancreatic beta-cells, and correlates with insulin expression. *Hum Mol Genet.* 2009;18(3):428–39. <https://doi.org/10.1093/hmg/ddn370>.
 41. Orci L. The insulin factory: a tour of the plant surroundings and a visit to the assembly line. The Minkowski lecture 1973 revisited. *Diabetologia.* 1985;28(8):528–46.
 42. In't Veld P, Marichal M. Microscopic anatomy of the human islet of Langerhans. *Adv Exp Med Biol.* 2010;654:1–19. https://doi.org/10.1007/978-90-481-3271-3_1.
 43. Ivanova A, Kalaidzidis Y, Dirx R, Sarov M, Gerlach M, Schroth-Diez B, et al. Age-dependent labeling and imaging of insulin secretory granules. *Diabetes.* 2013;62(11):3687–96. <https://doi.org/10.2337/db12-1819>.
 - 44.●● Xin Y, Kim J, Okamoto H, Ni M, Wei Y, Adler C, et al. RNA sequencing of single human islet cells reveals type 2 diabetes genes. *Cell Metab.* 2016;24(4):608–15. <https://doi.org/10.1016/j.cmet.2016.08.018>. **By using single-cell RNA sequencing this report demonstrated the cell type-specific genes and pathways that are altered in human with T2D.**
 45. Tritschler S, Theis FJ, Lickert H, Bottcher A. Systematic single-cell analysis provides new insights into heterogeneity and plasticity of the pancreas. *Mol Metab.* 2017;6(9):974–90. <https://doi.org/10.1016/j.molmet.2017.06.021>.
 - 46.●● Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. *Cell Metab.* 2016;24(4):593–607. <https://doi.org/10.1016/j.cmet.2016.08.020>. **This study demonstrated the comparison of single-cell transcriptomes between healthy and T2D human subjects.**
 47. Nishimura W, Kondo T, Salameh T, El Khattabi I, Dodge R, Bonner-Weir S, et al. A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells. *Dev Biol.* 2006;293(2):526–39. <https://doi.org/10.1016/j.ydbio.2006.02.028>.
 48. Arnter I, Hang Y, Mazur M, Yamamoto T, Guo M, Lindner J, et al. MafA and MafB regulate genes critical to beta-cells in a unique temporal manner. *Diabetes.* 2010;59(10):2530–9. <https://doi.org/10.2337/db10-0190>.
 49. Muraro MJ, Dharmadhikari G, Grun D, Groen N, Dielen T, Jansen E, et al. A single-cell transcriptome atlas of the human pancreas. *Cell Syst.* 2016;3(4):385–94.e3. <https://doi.org/10.1016/j.cels.2016.09.002>.
 - 50.●● Lawlor N, George J, Bolisetty M, Kursawe R, Sun L, Sivakamasundari V, et al. Single-cell transcriptomes identify

- human islet cell signatures and reveal cell-type-specific expression changes in type 2 diabetes. *Genome Res.* 2017;27(2):208–22. <https://doi.org/10.1101/gr.212720.116>. **This study revealed (in single cell level) genes differentially regulated between T2D and ND alpha, beta, and delta cells that were undetectable in paired whole islet analyses.**
51. Arda HE, Li L, Tsai J, Torre EA, Rosli Y, Peiris H, et al. Age-dependent pancreatic gene regulation reveals mechanisms governing human beta cell function. *Cell Metab.* 2016;23(5):909–20. <https://doi.org/10.1016/j.cmet.2016.04.002>.
 52. Qiu WL, Zhang YW, Feng Y, Li LC, Yang L, Xu CR. Deciphering pancreatic islet beta cell and alpha cell maturation pathways and characteristic features at the single-cell level. *Cell Metab.* 2017;25(5):1194–205.e4. <https://doi.org/10.1016/j.cmet.2017.04.003>.
 53. Bader E, Migliorini A, Gegg M, Moruzzi N, Gerdes J, Roscioni SS, et al. Identification of proliferative and mature beta-cells in the islets of Langerhans. *Nature.* 2016;535(7612):430–4. <https://doi.org/10.1038/nature18624>. **This report demonstrated a new technique to identify proliferative beta cells in adult islets.**
 54. Suissa Y, Magenheimer J, Stolovich-Rain M, Hija A, Collombat P, Mansouri A, et al. Gastrin: a distinct fate of neurogenin3 positive progenitor cells in the embryonic pancreas. *PLoS One.* 2013;8(8):e70397. <https://doi.org/10.1371/journal.pone.0070397>.
 55. Rodnoi P, Rajkumar M, Moin ASM, Georgia SK, Butler AE, Dhawan S. Neuropeptide Y expression marks partially differentiated β cells in mice and humans. *JCI insight.* 2017;2(12):e94005. <https://doi.org/10.1172/jci.insight.94005>. **This report highlighted the contribution of neuropeptide Y (NPY) in the regulation of β cell differentiation.**
 56. Dorrell C, Schug J, Canaday PS, Russ HA, Tarlow BD, Grompe MT, et al. Human islets contain four distinct subtypes of β cells. *Nat Commun.* 2016;7:11756. <https://doi.org/10.1038/ncomms11756>. **This report revealed the heterogeneity of human pancreatic β cell.**
 57. Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC. β cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. *Cell Metab.* 2017;25(3):727–38. <https://doi.org/10.1016/j.cmet.2017.01.005>.
 58. Wang YJ, Golson ML, Schug J, Traum D, Liu C, Vivek K, et al. Single-cell mass cytometry analysis of the human endocrine pancreas. *Cell Metab.* 2016;24(4):616–26. <https://doi.org/10.1016/j.cmet.2016.09.007>. **Analysis of human beta cells at single-cell level.**
 59. Johnston NR, Mitchell RK, Haythorne E, Pessoa MP, Semplici F, Ferrer J, et al. Beta cell hubs dictate pancreatic islet responses to glucose. *Cell Metab.* 2016;24(3):389–401. <https://doi.org/10.1016/j.cmet.2016.06.020>. **Elucidation of the mechanism of functional heterogeneity of beta cells.**
 60. Fang Z, Weng C, Li H, Tao R, Mai W, Liu X, et al. Single-cell heterogeneity analysis and CRISPR screen identify key β -cell-specific disease genes. *Cell Rep.* 2019;26(11):3132–44.e7. <https://doi.org/10.1016/j.celrep.2019.02.043>. **This report described a new algorithm to interpret the single-cell heterogeneity analysis of different subpopulations of beta cells.**
 61. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC. Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. *Diabetologia.* 2006;49(11):2689–96. <https://doi.org/10.1007/s00125-006-0410-5>.
 62. Butler AE, Cao-Minh L, Galasso R, Rizza RA, Corradin A, Cobelli C, et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. *Diabetologia.* 2010;53(10):2167–76. <https://doi.org/10.1007/s00125-010-1809-6>.
 63. Costes S, Langen R, Gurlo T, Matveyenko AV, Butler PC. β -Cell failure in type 2 diabetes: a case of asking too much of too few? *Diabetes.* 2013;62(2):327–35. <https://doi.org/10.2337/db12-1326>.
 64. Wang H, Bender A, Wang P, Karakose E, Inabnet WB, Libutti SK, et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. *Nat Commun.* 2017;8(1):767. <https://doi.org/10.1038/s41467-017-00992-9>.
 65. Holmberg J, Perlmann T. Maintaining differentiated cellular identity. *Nat Rev Genet.* 2012;13(6):429–39. <https://doi.org/10.1038/nrg3209>.
 66. Weir GC, Aguayo-Mazzucato C, Bonner-Weir S. β -Cell dedifferentiation in diabetes is important, but what is it? *Islets.* 2013;5(5):233–7. <https://doi.org/10.4161/isl.27494>.
 67. Sachdeva MM, Claiborn KC, Khoo C, Yang J, Groff DN, Mirmira RG, et al. Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress. *Proc Natl Acad Sci U S A.* 2009;106(45):19090–5. <https://doi.org/10.1073/pnas.0904849106>.
 68. Kluth O, Mirhashemi F, Scherneck S, Kaiser D, Kluge R, Neschen S, et al. Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. *Diabetologia.* 2011;54(3):605–16. <https://doi.org/10.1007/s00125-010-1973-8>.
 69. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, et al. Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. *Am J Pathol.* 2011;178(6):2632–40. <https://doi.org/10.1016/j.ajpath.2011.02.036>.
 70. Vierbuchen T, Wernig M. Direct lineage conversions: unnatural but useful? *Nat Biotechnol.* 2011;29(10):892–907. <https://doi.org/10.1038/nbt.1946>.
 71. Sapir T, Shternhall K, Meivar-Levy I, Blumenfeld T, Cohen H, Skutelsky E, et al. Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells. *Proc Natl Acad Sci U S A.* 2005;102(22):7964–9. <https://doi.org/10.1073/pnas.0405277102>.
 72. Dor Y, Glaser B. β -Cell dedifferentiation and type 2 diabetes. *N Engl J Med.* 2013;368(6):572–3. <https://doi.org/10.1056/NEJMcibr1214034>.
 73. Alán L, Olejár T, Cahová M, Zelenka J, Berková Z, Smětáková M, et al. Delta cell hyperplasia in adult Goto-Kakizaki (GK/MolTac) diabetic rats. *J Diabetes Res.* 2015;2015:385395–16. <https://doi.org/10.1155/2015/385395>.
 74. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. *J Clin Invest.* 1970;49(4):837–48. <https://doi.org/10.1172/jci106297>.
 75. Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, Billestrup N, et al. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. *Cell.* 2009;138(3):449–62. <https://doi.org/10.1016/j.cell.2009.05.035>.
 76. Courtney M, Gjernes E, Druelle N, Ravaud C, Vieira A, Ben-Othman N, et al. The inactivation of Arx in pancreatic α -cells triggers their neogenesis and conversion into functional β -like cells. *PLoS Genet.* 2013;9(10):e1003934. <https://doi.org/10.1371/journal.pgen.1003934>.
 77. Wilcox CL, Terry NA, Walp ER, Lee RA, May CL. Pancreatic α -cell specific deletion of mouse Arx leads to α -cell identity loss. *PLoS One.* 2013;8(6):e66214. <https://doi.org/10.1371/journal.pone.0066214>.
 78. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. *Proc Natl Acad Sci U S A.* 2010;107(37):16009–12. <https://doi.org/10.1073/pnas.1006639107>.

79. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. *J Clin Invest*. 2012;122(1):4–12. <https://doi.org/10.1172/JCI60016>.
80. Bonner-Weir S, Inada A, Yatoh S, Li WC, Aye T, Toschi E, et al. Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. *Biochem Soc Trans*. 2008;36(Pt 3):353–6. <https://doi.org/10.1042/BST0360353>.
81. Park MK, Han C, Lee KH, Hong SH, Kim HS, Lee YJ, et al. Effects of activin A on pancreatic ductal cells in streptozotocin-induced diabetic rats. *Transplantation*. 2007;83(7):925–30. <https://doi.org/10.1097/01.tp.0000259978.62139.9d>.
82. Kim HS, Hong SH, Oh SH, Kim JH, Lee MS, Lee MK. Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells. *J Endocrinol*. 2013;217(3):241–52. <https://doi.org/10.1530/JOE-12-0474>.
83. Moin AS, Butler PC, Butler AE. Increased proliferation of the pancreatic duct gland compartment in type 1 diabetes. *J Clin Endocrinol Metab*. 2017;102(1):200–9. <https://doi.org/10.1210/jc.2016-3001>. **This study demonstrated pancreatic duct gland compartment (PDG) as a potential source of pancreatic endocrine cell regeneration in type 1 diabetes.**
84. White MG, Marshall HL, Rigby R, Huang GC, Amer A, Booth T, et al. Expression of mesenchymal and α -cell phenotypic markers in islet β -cells in recently diagnosed diabetes. *Diabetes Care*. 2013;36(11):3818–20. <https://doi.org/10.2337/dc13-0705>.
85. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. *Diabetes*. 2013;62(7):2595–604. <https://doi.org/10.2337/db12-1686>.
86. Dahan T, Ziv O, Horwitz E, Zemmour H, Lavi J, Swisa A, et al. Pancreatic β -cells express the fetal islet hormone gastrin in rodent and human diabetes. *Diabetes*. 2017;66(2):426–36. <https://doi.org/10.2337/db16-0641>.
87. Moin AS, Dhawan S, Shieh C, Butler PC, Cory M, Butler AE. Increased hormone-negative endocrine cells in the pancreas in type 1 diabetes. *J Clin Endocrinol Metab*. 2016;101(9):3487–96. <https://doi.org/10.1210/jc.2016-1350>. **This study demonstrated the altered β cell identity in human with T1D.**
88. Moin AS, Cory M, Ong A, Choi J, Dhawan S, Butler PC, et al. Pancreatic nonhormone expressing endocrine cells in children with type 1 diabetes. *J Endocr Soc*. 2017;1(5):385–95. <https://doi.org/10.1210/js.2017-00081>.
89. Moin AS, Dhawan S, Cory M, Butler PC, Rizza RA, Butler AE. Increased frequency of hormone negative and polyhormonal endocrine cells in lean individuals with type 2 diabetes. *J Clin Endocrinol Metab*. 2016;101(10):3628–36. <https://doi.org/10.1210/jc.2016-2496>. **This study revealed the increased frequency of altered β cells in lean human with T2D and that alteration preceded the onset of T2D in a diabetic animal model.**
90. Moin ASM, Montemurro C, Zeng K, Cory M, Nguyen M, Kulkarni S, et al. Characterization of non-hormone expressing endocrine cells in fetal and infant human pancreas. *Front Endocrinol (Lausanne)*. 2018;9:791. <https://doi.org/10.3389/fendo.2018.00791>. **This report showed the frequency of altered β cells in fetal and infant human pancreas.**
91. Meier JJ, Lin JC, Butler AE, Galasso R, Martinez DS, Butler PC. Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. *Diabetologia*. 2006;49(8):1838–44. <https://doi.org/10.1007/s00125-006-0308-2>.
92. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. *Diabetologia*. 2010;53(9):2020–8. <https://doi.org/10.1007/s00125-010-1817-6>.
93. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. *J Clin Endocrinol Metab* 1987;65(1):30–6. doi:<https://doi.org/10.1210/jcem-65-1-30>.
94. Sørensen JS, Johannesen J, Pociot F, Kristensen K, Thomsen J, Hertel NT, et al. Residual β -cell function 3–6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. *Diabetes Care*. 2013;36(11):3454–9. <https://doi.org/10.2337/dc13-0418>.
95. Oram RA, Sims EK, Evans-Molina C. Beta cells in type 1 diabetes: mass and function; sleeping or dead? *Diabetologia*. 2019;62(4):567–77. <https://doi.org/10.1007/s00125-019-4822-4>.
96. Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, et al. Proinsulin secretion is a persistent feature of type 1 diabetes. *Diabetes Care*. 2019;42(2):258–64. <https://doi.org/10.2337/dc17-2625>. **This report highlighted the functional β cell mass in long-standing T1D.**
97. Wasserfall C, Nick HS, Campbell-Thompson M, Beachy D, Haataja L, Kusmartseva I, et al. Persistence of pancreatic insulin mRNA expression and proinsulin protein in type 1 diabetes pancreata. *Cell Metab*. 2017;26(3):568–75.e3. <https://doi.org/10.1016/j.cmet.2017.08.013>. **This report demonstrated the functional capacity of residual β cells in T1D.**
98. Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. *Cell Metab*. 2014;19(5):872–82. <https://doi.org/10.1016/j.cmet.2014.03.010>.
99. Burke GW, Posgai AL, Wasserfall CH, Atkinson MA, Pugliese A. Raising awareness: the need to promote allocation of pancreata from rare nondiabetic donors with pancreatic islet autoimmunity to type 1 diabetes research. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg*. 2017;17(1):306–7. <https://doi.org/10.1111/ajt.13983>. **This report focuses the importance of pancreatic organ donation to study the pathogenesis of T1D.**
100. Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, et al. Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes. *Diabetes*. 2017;66(3):722–34. <https://doi.org/10.2337/db16-1025>.
101. Eguchi K, Manabe I. Macrophages and islet inflammation in type 2 diabetes. *Diabetes Obes Metab*. 2013;15(Suppl 3):152–8. <https://doi.org/10.1111/dom.12168>.
102. Nordmann TM, Dror E, Schulze F, Traub S, Berishvili E, Barbieux C, et al. The role of inflammation in beta-cell dedifferentiation. *Sci Rep*. 2017;7(1):6285. <https://doi.org/10.1038/s41598-017-06731-w>. **This report demonstrated that inflammation causes β cell dedifferentiation in vitro.**
103. Dalgaard LT, Eliasson L. An ‘alpha-beta’ of pancreatic islet microribonucleotides. *Int J Biochem Cell Biol*. 2017;88:208–19. <https://doi.org/10.1016/j.biocel.2017.01.009>.
104. Dhawan S, Georgia S, Tschien SI, Fan G, Bhushan A. Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of Arx. *Dev Cell*. 2011;20(4):419–29. <https://doi.org/10.1016/j.devcel.2011.03.012>. **This report described the importance of epigenetic modifications in maintenance of beta cell identity.**
105. Lu TT, Heyne S, Dror E, Casas E, Leonhardt L, Boenke T, et al. The polycomb-dependent epigenome controls beta cell dysfunction, dedifferentiation, and diabetes. *Cell Metab*. 2018;27(6):1294–308.e7. <https://doi.org/10.1016/j.cmet.2018.04.013>. **A new proposed mechanism of epigenetic regulation pancreatic beta cell biology.**

106. Davegårdh C, García-Calzón S, Bacos K, Ling C. DNA methylation in the pathogenesis of type 2 diabetes in humans. *Mol Metab.* 2018;14:12–25. <https://doi.org/10.1016/j.molmet.2018.01.022>. **This study demonstrated the role of epigenetics in the pathogenesis of T2D.**
107. Oshima M, Knoch KP, Diedisheim M, Petzold A, Cattan P, Bugliani M, et al. Virus-like infection induces human beta cell dedifferentiation. *JCI insight.* 2018;3(3):e97732. <https://doi.org/10.1172/jci.insight.97732>.
108. Keisuke Kitakaze, Kurahashi Kioye MM, Hamada Yoshimasa, Oyadomari Miho, Oyadomari Seiichi. Targeted deletion of ATF4 in β cells leads to the vulnerability and dedifferentiation during ER stress. *Diabetes.* 2018;67. <https://doi.org/10.2337/db18-2104-P>.
109. Chan JY, Luzuriaga J, Bensellam M, Biden TJ, Laybutt DR. Failure of the adaptive unfolded protein response in islets of obese mice is linked with abnormalities in β -cell gene expression and progression to diabetes. *Diabetes.* 2013;62(5):1557–68. <https://doi.org/10.2337/db12-0701>.
110. Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, et al. Islet β -cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. *Diabetes.* 2012;61(4):818–27. <https://doi.org/10.2337/db11-1293>.
111. Moin ASM, Cory M, Choi J, Ong A, Dhawan S, Dry SM, et al. Increased chromogranin A-positive hormone negative cells in chronic pancreatitis. *J Clin Endocrinol Metab.* 2018;103:2126–35. <https://doi.org/10.1210/jc.2017-01562>.
112. Bensellam M, Jonas JC, Laybutt DR. Mechanisms of beta-cell dedifferentiation in diabetes: recent findings and future research directions. *J Endocrinol.* 2018;236(2):R109–r43. <https://doi.org/10.1530/joe-17-0516>. **An integrative review on β cell dedifferentiation and factors associated with that phenomenon.**
113. Matveyenko AV, Butler PC. Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. *Diabetes.* 2006;55(7):2106–14. <https://doi.org/10.2337/db05-1672>.
114. Panagiotopoulos C, Qin H, Tan R, Verchere CB. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. *Diabetes.* 2003;52(11):2647–51. <https://doi.org/10.2337/diabetes.52.11.2647>.
115. Standifer NE, Ouyang Q, Panagiotopoulos C, Verchere CB, Tan R, Greenbaum CJ, et al. Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. *Diabetes.* 2006;55(11):3061–7. <https://doi.org/10.2337/db06-0066>.
116. Baker RL, DeLong T, Barbour G, Bradley B, Nakayama M, Haskins K. Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice. *J Immunol.* 2013;191(8):3990–4. <https://doi.org/10.4049/jimmunol.1301480>.
117. Wiles TA, DeLong T, Baker RL, Bradley B, Barbour G, Powell RL, et al. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. *J Autoimmun.* 2017;78:11–8. <https://doi.org/10.1016/j.jaut.2016.10.007>.
118. Beery ML, Jacobsen LM, Atkinson MA, Butler AE, Campbell-Thompson M. Islet amyloidosis in a child with type 1 diabetes. *Islets.* 2019;11(2):44–9. <https://doi.org/10.1080/19382014.2019.1599707>.
119. Westermark GT, Krogvold L, Dahl-Jørgensen K, Ludvigsson J. Islet amyloid in recent-onset type 1 diabetes—the DiViD study. *Ups J Med Sci.* 2017;122(3):201–3. <https://doi.org/10.1080/03009734.2017.1359219>. **This report described amyloidosis of islets in patients with T1D.**
120. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. *J Clin Invest.* 2006;116(7):1802–12. <https://doi.org/10.1172/jci29103>.
121. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. *Science (New York, NY).* 2011;334(6059):1081–6. <https://doi.org/10.1126/science.1209038>.
122. Courtney M, Gjernes E, Druelle N, Ravaud C, Vieira A, Ben-Othman N, et al. The inactivation of Arx in pancreatic alpha-cells triggers their neogenesis and conversion into functional beta-like cells. *PLoS Genet.* 2013;9(10):e1003934. <https://doi.org/10.1371/journal.pgen.1003934>.
123. Papizan JB, Singer RA, Tschen SI, Dhawan S, Friel JM, Hipkens SB, et al. Nkx2.2 repressor complex regulates islet beta-cell specification and prevents beta-to-alpha-cell reprogramming. *Genes Dev.* 2011;25(21):2291–305. <https://doi.org/10.1101/gad.173039.111>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.